The US Department of Health and Human Services Office of Inspector General (OIG) has issued an advisory opinion that may impact how cochlear implant manufacturers offer their products to potential patients. In its Advisory Opinion No. 23-08, posted on October 25, 2023, the OIG rejected a proposed arrangement from a cochlear implant device manufacturer that had planned to provide a free hearing aid to certain qualified patients as part of its product offering.
The manufacturer, referred to as the requestor in the advisory opinion, sought to broaden its market reach by offering a free hearing aid to those who had already received a cochlear implant from it. Although granting hearing aids to qualified patients seems beneficial, the OIG has interpreted this arrangement as a potential violation of anti-kickback statutes and other abuse laws within the health care industry.
As legal professionals working within both corporate and individual medical device manufacturers, it’s crucial to comprehend and align business strategies with the legal perspectives presented in such advisory opinions. Misinterpretations or overlooking could lead to serious legal repercussions, including violations of fraud and abuse laws.
More details about key elements such as the reasoning behind the OIG’s decision, potential implications for the cochlear implant manufacturer, and potential consequences for other health device manufacturers, remain to be clarified. Nonetheless, this latest development is an important reminder for the health care and legal industry about the strict regulatory scrutiny in health care initiatives.
The full advisory opinion by the OIG can be accessed through Morgan Lewis’ Health Law Scan for further understanding and future reference.